Search

Displaying 41 - 50 of 456

The new NKF Patient Network will help improve the lives of people with kidney disease through research, clinical care, drug development, and supportive health policy decisions

February 25, 2021, New York, NY —Today the National Kidney Foundation (NKF) launched the first-ever national registry for patients at all stages of kidney disease, the NKF Patient Network. This powerful...

New York, NY—December 3, 2020—Kidney disease is a public health crisis and the National Kidney Foundation (NKF) is calling on the Biden-Harris Administration to make it a top priority during their first 100 days in office. Affecting 37 million adults in the U.S., kidney disease sits at the intersection of three forces that will shape health care during...

Program focused on improving disease management and outcomes beginning at the primary care level 

Dec. 2, 2020, New York, NY —The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in the earliest stage of the disease that will ultimately guide clinical interventions and treatments for...

Drug treatment study released in American Journal of Kidney Diseases

 

Sept. 21, 2020—New York, NY – A new study released today in the National Kidney Foundation’s  American Journal of Kidney Diseases (AJKD) shows that the drug canagliflozin reduces the risk of adverse cardiovascular and kidney outcomes in people...

(April 18, 2024, New York, NY) — The National Kidney Foundation (NKF) proudly announces that Robert A. Montgomery, MD, DPhil, FACS, is the 2024 recipient of the prestigious Excellence in Transplantation Award. Currently, Dr. Montgomery is the H. Leon Pachter Chairman and Professor of Surgery at New York...

A joint statement from the National Kidney Foundation and the American Society of Nephrology July 2, 2020

 

Of the more than 37 million people affected by kidney diseases in the United States, a disproportionate number are of African American, Hispanic, Asian, and Native American descent. African Americans are three times more likely than Non-Hispanic Whites to experience kidney failure. Such disparities go beyond the high...

Investigators present work at the National Kidney Foundation’s virtual Spring Clinicals Meetings   March 25, 2020, New York, NY—Today, the National Kidney Foundation (NKF) showcased a global study designed to understand the experimental immunosuppressant drug Voclosporin as a treatment for patients with lupus kidney disease.    The important study, ...
National Kidney Foundation and CareFirst partnered for the first time on landmark study   New York, NY – November 12, 2019 -  A new study conducted by the National Kidney Foundation and CareFirst BlueCross BlueShield (CareFirst) found that detecting chronic kidney disease (CKD) with two...
  The National Kidney Foundation Statement about INVOKANA® (Canagliflozin)   New York, NY–Sept. 30, 2019— “The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that their drug INVOKANA® (Canagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease (...
  VICTORIA, British Columbia - (BUSINESS WIRE) - March 14, 2019 - In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with the National Kidney...